Jasper Therapeutics Clinical Trial Data
Jasper Therapeutics completed enrollment for the IgA nephropathy (IgAN) cohort of its Phase 2 basket study evaluating vensobafusp alfa (KP104). The company expects to report initial interim data from this study by year-end 2026 and plans to expand the study to include patients with focal segmental glomerulosclerosis (FSGS) in early 2027.